-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to Q1 2025.
- Verve Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2025 was -$36.6M, a 35.6% increase year-over-year.
- Verve Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2025 was -$208M, a 5.98% increase year-over-year.
- Verve Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$229M, a 2.48% decline from 2023.
- Verve Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$223M, a 34.7% decline from 2022.
- Verve Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$166M, a 90.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)